X
NKTR icon

Xponance’s Nektar Therapeutics NKTR Stock Holding History

Xponance’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$236K Buy
+3,374
New +$247K ﹤0.01% 1531
2025
Q2 		– Sell
-813
Closed -$8.29K – 1531
2025
Q1 		$8.29K Buy
813
+20
+3% +$261 ﹤0.01% 1441
2024
Q4 		$11.1K Buy
793
+73
+10% +$1.29K ﹤0.01% 1439
2024
Q3 		$14K Sell
720
-44
-6% -$839 ﹤0.01% 1385
2024
Q2 		$14.2K Buy
+764
New +$16.1K ﹤0.01% 1313
2023
Q2 		– Sell
-689
Closed -$7.27K – 1278
2023
Q1 		$7.27K Hold
689
– – ﹤0.01% 1234
2022
Q4 		$23.4K Buy
689
+11
+2% +$532 ﹤0.01% 1210
2022
Q3 		$33K Buy
+678
New +$40.3K ﹤0.01% 1166
2021
Q4 		– Sell
-1,376
Closed -$371K – 1187
2021
Q3 		$371K Sell
1,376
-46
-3% -$11.1K 0.01% 995
2021
Q2 		$366K Buy
1,422
+142
+11% +$39.3K 0.01% 1022
2021
Q1 		$384K Buy
1,280
+26
+2% +$8.09K 0.01% 886
2020
Q4 		$320K Sell
1,254
-2
-0.2% -$517 0.01% 933
2020
Q3 		$312K Buy
1,256
+185
+17% +$58.2K 0.01% 843
2020
Q2 		$372K Buy
+1,071
New +$334K 0.01% 748

Other funds holding NKTR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Xponance's NKTR Position: Q2 2026 in Review

Xponance opened a new position in Nektar Therapeutics (NKTR) in Q2 2026: 3,374 shares worth $236K. The stake represents ﹤0.01% of the portfolio and ranks #1531 among its holdings. This is a return to the name: Xponance previously reported a position in NKTR as recently as Q1 2025.

Xponance first reported a position in NKTR in Q2 2020 and has held it in 14 quarters since. The position peaked at $384K in Q1 2021. 240 funds tracked by Wall St. Rank hold NKTR as of Q2 2026.

  • Xponance held 3,374 shares of Nektar Therapeutics worth $236K as of Q2 2026.
  • Nektar Therapeutics was a new Xponance position in Q2 2026.
  • Nektar Therapeutics made up ﹤0.01% of Xponance's portfolio in Q2 2026, its #1531 holding.
  • Xponance first reported a position in Nektar Therapeutics in Q2 2020 and has held it in 14 quarters since.
  • Xponance's Nektar Therapeutics position peaked at $384K in Q1 2021.
  • 240 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2026.

Based on Xponance's 13F filing for Q2 2026, filed 10 Aug 2026.